Save time and get answers to complex questions with AI chat
Bortezomib market france?When will tenofovir alafenide come off patent in canada?Defitelio defibrotide sodium drug profile 2024 drugpatentwatch?Bivalirudin manufacturer?Prolia and osteonecrosis?
See the DrugPatentWatch profile for lokelma
Lokelma (sodium zirconium cyclosilicate) is indicated for the treatment of hyperkalemia (elevated potassium) in adults and in pediatric patients aged 2 years and older. It binds potassium in the GI tract to help lower serum potassium. Not intended for emergent treatment of life-threatening hyperkalemia.
Other Questions About Lokelma :